AR074089A1 - Antagonistas de cicloalcano (b) azaindol de los receptores de la postaglandina d2 - Google Patents

Antagonistas de cicloalcano (b) azaindol de los receptores de la postaglandina d2

Info

Publication number
AR074089A1
AR074089A1 ARP090104282A ARP090104282A AR074089A1 AR 074089 A1 AR074089 A1 AR 074089A1 AR P090104282 A ARP090104282 A AR P090104282A AR P090104282 A ARP090104282 A AR P090104282A AR 074089 A1 AR074089 A1 AR 074089A1
Authority
AR
Argentina
Prior art keywords
substituted
alkyl
pgd2
unsubstituted
heteroalkyl
Prior art date
Application number
ARP090104282A
Other languages
English (en)
Original Assignee
Amira Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amira Pharmaceuticals Inc filed Critical Amira Pharmaceuticals Inc
Publication of AR074089A1 publication Critical patent/AR074089A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

En la presente se describen compuestos que son antagonistas de receptores de la PGD2. También, se describen composiciones farmacéuticas que incluyen los compuestos que se describen en la presente, así como los métodos para la utilizacion de dichos antagonistas de ?os receptores de la PGD2, solos o en combinacion con otros compuestos, para el tratamiento de condiciones o enfermedades respiratorias, cardiovasculares y otras condiciones o enfermedades dependientes de la PGD2 o mediadas por la PGD2. Reivindicacion 1: Un compuesto que tiene la estructura de la formula (1), sal aceptable desde el punto de vista farmacéutico o N-oxido del mismo, caracterizado porque cada RA es independientemente H, F, Cl, Br, I, -CN, -NO2, alquilo C1-4, fluoroalquilo C1-4, fluoroalcoxi C1-4, alcoxi C1-4, o heteroalquilo C1-4; R2 es H o alquilo C1-4; R3 es H, alquilo C1-4, fluoroalquilo C1-4 o -L3-X3; -L3- es -alquileno C1-4-; -X3 es H, F, -CN, -CO2R13, -C(=O)N(R13)2, tetrazolilo, u -OH; R12 es alquilo C1-6, haloalquilo C1-6, heteroalquilo C1-6, un fenilo substituido o no substituido, un naftilo substituido o no substituido, un heteroarilo monocíclico substituido o no substituido o un heteroarilo bicíclico substituido o no substituido, caracterizado porque si R12 es substituido entonces R12 es substituido con 1 o 2 R14; cada R14 es independientemente H, F, Cl, Br, I, -CN, -NH2 -OH, -NH(CH3), -N(CH3)2, alquilo C1-4, fluoroalquilo C1-4, alcoxi C1-4, fluoroalcoxi C1-4, o heteroalquilo C1-4; cada R13 es independientemente H, alquilo C1-4, o un fenilo substituido o no substituido; n es 1 o 2; p es 0, 1 o 2.
ARP090104282A 2008-11-06 2009-11-05 Antagonistas de cicloalcano (b) azaindol de los receptores de la postaglandina d2 AR074089A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11204408P 2008-11-06 2008-11-06

Publications (1)

Publication Number Publication Date
AR074089A1 true AR074089A1 (es) 2010-12-22

Family

ID=42132183

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090104282A AR074089A1 (es) 2008-11-06 2009-11-05 Antagonistas de cicloalcano (b) azaindol de los receptores de la postaglandina d2

Country Status (6)

Country Link
US (2) US8034826B2 (es)
AR (1) AR074089A1 (es)
GB (1) GB2465062B (es)
TW (1) TW201022265A (es)
UY (1) UY32225A (es)
WO (2) WO2010054113A2 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009061681A2 (en) * 2007-11-06 2009-05-14 Amira Pharmaceuticals, Inc Antagonists of pgd2 receptors
WO2009061676A2 (en) * 2007-11-06 2009-05-14 Amira Pharmaceuticals, Inc. Antagonists of pgd2 receptors
BRPI0907364A2 (pt) 2008-02-01 2015-07-14 Amira Pharmaceuticals Inc Antagonistas aminoalquilbifenil n,n-disubstituídos de receptores d2 de prostaglandina
WO2009099901A1 (en) * 2008-02-01 2009-08-13 Amira Pharmaceuticals, Inc. N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors
WO2009102893A2 (en) * 2008-02-14 2009-08-20 Amira Pharmaceuticals, Inc. CYCLIC DIARYL ETHER COMPOUNDS AS ANTAGONISTS OF PROSTAGLANDIN D2 receptors
JP2011513242A (ja) * 2008-02-25 2011-04-28 アミラ ファーマシューティカルズ，インク． プロスタグランジンｄ２受容体アンタゴニスト
US8426449B2 (en) * 2008-04-02 2013-04-23 Panmira Pharmaceuticals, Llc Aminoalkylphenyl antagonists of prostaglandin D2 receptors
US20110112134A1 (en) * 2008-05-16 2011-05-12 Amira Pharmaceuticals, Inc. Tricyclic Antagonists of Prostaglandin D2 Receptors
JP2011526281A (ja) 2008-06-24 2011-10-06 アミラ ファーマシューティカルズ，インク． プロスタグランジンｄ２受容体のシクロアルカン［ｂ］インドールアンタゴニスト
GB2463788B (en) * 2008-09-29 2010-12-15 Amira Pharmaceuticals Inc Heteroaryl antagonists of prostaglandin D2 receptors
US8378107B2 (en) 2008-10-01 2013-02-19 Panmira Pharmaceuticals, Llc Heteroaryl antagonists of prostaglandin D2 receptors
US8524748B2 (en) 2008-10-08 2013-09-03 Panmira Pharmaceuticals, Llc Heteroalkyl biphenyl antagonists of prostaglandin D2 receptors
GB2465062B (en) 2008-11-06 2011-04-13 Amira Pharmaceuticals Inc Cycloalkane(B)azaindole antagonists of prostaglandin D2 receptors
WO2010057118A2 (en) 2008-11-17 2010-05-20 Amira Pharmaceuticals, Inc. Heterocyclic antagonists of prostaglandin d2 receptors
US20100173313A1 (en) * 2009-01-08 2010-07-08 Amira Pharmaceuticals, Inc. Biomarkers of inflammation
CN102596199A (zh) 2009-07-31 2012-07-18 潘米拉制药公司 Dp2受体拮抗剂的眼用医药组合物
CN102596902A (zh) * 2009-08-05 2012-07-18 潘米拉制药公司 Dp2拮抗剂及其用途
BR112012024114B1 (pt) 2010-03-22 2021-02-09 Idorsia Pharmaceuticals Ltd Compostos derivados de 3-(heteroarilamino)-1,2,3,4-tetrahidro-9h-carbazol, uso dos mesmos, e, composição farmacêutica
EP2457900A1 (en) 2010-11-25 2012-05-30 Almirall, S.A. New pyrazole derivatives having CRTh2 antagonistic behaviour
BR112013026283A8 (pt) 2011-04-14 2018-01-30 Actelion Pharmaceuticals Ltd derivados de ácido 7-(heteroaril-amino)-6,7,8,9-tetrahidropirido[1,2-a]indol acético e seu uso como moduladores do receptor d2 de prostaglandina
EP3382391A1 (en) 2012-10-24 2018-10-03 NYU Winthrop Hospital Non-invasive biomarker to identify subjects at risk of preterm delivery
SI3119779T1 (sl) 2014-03-17 2018-10-30 Idorsia Pharmaceuticals Ltd Derivati azaindolocetne kisline in njihova uporaba kot modulatorji prostaglandinskega receptorja D2
AU2015233046A1 (en) 2014-03-18 2016-11-03 Idorsia Pharmaceuticals Ltd Azaindole acetic acid derivatives and their use as prostaglandin D2 receptor modulators
WO2017046125A1 (en) * 2015-09-15 2017-03-23 Actelion Pharmaceuticals Ltd Crystalline forms
US20200264188A1 (en) 2017-09-13 2020-08-20 Progenity, Inc. Preeclampsia biomarkers and related systems and methods
WO2019166635A1 (en) 2018-03-01 2019-09-06 Universität Basel Vizerektorat Forschung Dielectric elastomer transducer and corresponding fabrication process
EP4070113A4 (en) 2019-12-04 2023-12-20 Biora Therapeutics, Inc. ASSESSMENT OF PREECAMPSIA USING FREE AND DISSOCIATE PLACENTAL GROWTH FACTOR ASSAYS
CN111166899A (zh) * 2020-01-07 2020-05-19 安徽省双科药业有限公司 山梨醇滴眼液湿热灭菌方法
CN115466776A (zh) * 2022-09-26 2022-12-13 中国医学科学院基础医学研究所 检测嗜酸性粒细胞的试剂、嗜酸性粒细胞及其胞质内容物和羟基二十二碳六烯酸的应用

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4027278A1 (de) * 1990-08-29 1992-03-05 Bayer Ag Heterocyclisch substituierte indolsulfonamide
US6878522B2 (en) 2000-07-07 2005-04-12 Baiyong Li Methods for the identification of compounds useful for the treatment of disease states mediated by prostaglandin D2
JP2002076352A (ja) * 2000-08-31 2002-03-15 Semiconductor Energy Lab Co Ltd 表示装置及びその作製方法
EP1383771A1 (en) 2001-04-20 2004-01-28 Vertex Pharmaceuticals Incorporated 9-deazaguanine derivatives as inhibitors of gsk-3
EP1395590B1 (en) * 2001-05-23 2006-09-27 Merck Frosst Canada & Co. Dihydropyrrolo¬1,2-a|indole and tetrahydropyrido¬1,2-a|indole derivatives as prostaglandin d2 receptor antagonists
AR038136A1 (es) 2002-01-24 2004-12-29 Merck Frosst Canada Inc Cicloalcanindoles con sustitucion con fluor composiciones que contienen estos compuestos y metodos de tratamiento
EP2423190A1 (en) * 2002-05-16 2012-02-29 Shionogi&Co., Ltd. Compounds Exhibiting PGD 2 Receptor Antagonism
JP2006511486A (ja) 2002-10-21 2006-04-06 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー Ｃｒｔｈ２拮抗剤としてのテトラヒドロキノリン誘導体
MXPA05004715A (es) * 2002-10-30 2005-08-03 Merck Frosst Canada Inc Derivados de piridopirrolizina y piridoindolizina.
JP2004182657A (ja) 2002-12-04 2004-07-02 Eisai Co Ltd Ｈｄｌレベル上昇促進剤
AU2003297398B2 (en) 2002-12-20 2009-09-24 Amgen Inc. Asthma and allergic inflammation modulators
EP1471057B1 (en) 2003-04-25 2006-01-18 Actimis Pharmaceuticals, Inc. Pyrimidinylacetic acid derivatives useful for the treatment of diseases mediated by CRTH2
US20070232681A1 (en) 2003-10-14 2007-10-04 Oxagen Limited Compounds Having Crth2 Antagonist Activity
GB0324763D0 (en) 2003-10-23 2003-11-26 Oxagen Ltd Use of compounds in therapy
US7714132B2 (en) 2004-03-11 2010-05-11 Actelion Pharmaceuticals, Ltd. Tetrahydropyridoindole derivatives
WO2006052798A2 (en) * 2004-11-08 2006-05-18 Merck & Co., Inc. Method of treating pathological blushing
NZ556657A (en) * 2004-12-27 2010-10-29 Actelion Pharmaceuticals Ltd 2,3,4,9-tetrahydro-1H-carbazole derivatives as CRTH2 receptor antagonists
WO2007019675A1 (en) 2005-08-12 2007-02-22 Merck Frosst Canada Ltd. Indole derivatives as crth2 receptor antagonists
RU2405770C2 (ru) 2005-09-27 2010-12-10 Сионоги Энд Ко., Лтд. Производное сульфонамида, обладающее антагонистической активностью в отношении рецептора pgd2
EP1998766A2 (en) * 2005-12-16 2008-12-10 Ironwood Pharmaceuticals, Inc. Useful indole compounds
GB0605743D0 (en) 2006-03-22 2006-05-03 Oxagen Ltd Salts with CRTH2 antagonist activity
GB0611695D0 (en) 2006-06-13 2006-07-26 Novartis Ag Organic compounds
CA2660704A1 (en) 2006-08-07 2008-02-14 Ironwood Pharmaceuticals, Inc. Indole compounds
NZ574705A (en) * 2006-08-07 2011-12-22 Actelion Pharmaceuticals Ltd (3-amino-1,2,3,4-tetrahydro-9h-carbazol-9-yl)-acetic acid derivatives
US7960567B2 (en) 2007-05-02 2011-06-14 Amgen Inc. Compounds and methods useful for treating asthma and allergic inflammation
WO2008156780A1 (en) 2007-06-21 2008-12-24 Actimis Pharmaceuticals, Inc. Particulates of a crth2 antagonist
UA100983C2 (ru) 2007-07-05 2013-02-25 Астразенека Аб Бифенилоксипропановая кислота как модулятор crth2 и интермедиаты
GB0719521D0 (en) 2007-10-05 2007-11-14 Argenta Discovery Ltd Compounds
CN101896178B (zh) * 2007-10-10 2013-11-20 北京赛林泰医药技术有限公司 作为crth2受体拮抗剂的杂环化合物
GB0722216D0 (en) 2007-11-13 2007-12-27 Oxagen Ltd Use of crth2 antagonist compounds
GB0722203D0 (en) 2007-11-13 2007-12-19 Oxagen Ltd Use of CRTH2 antagonist compounds
CN101932571B (zh) * 2008-01-18 2014-04-23 奥克萨根有限公司 具有crth2拮抗活性的化合物
US20110112134A1 (en) 2008-05-16 2011-05-12 Amira Pharmaceuticals, Inc. Tricyclic Antagonists of Prostaglandin D2 Receptors
JP2011526281A (ja) 2008-06-24 2011-10-06 アミラ ファーマシューティカルズ，インク． プロスタグランジンｄ２受容体のシクロアルカン［ｂ］インドールアンタゴニスト
GB2465062B (en) 2008-11-06 2011-04-13 Amira Pharmaceuticals Inc Cycloalkane(B)azaindole antagonists of prostaglandin D2 receptors
WO2010085820A2 (en) 2009-01-26 2010-07-29 Amira Pharmaceuticals, Inc. Tricyclic compounds as antagonists of prostaglandin d2 receptors
WO2011014588A2 (en) 2009-07-31 2011-02-03 Amira Pharmaceuticals, Inc. Dermal formulations of dp2 receptor antagonists
CN102596199A (zh) 2009-07-31 2012-07-18 潘米拉制药公司 Dp2受体拮抗剂的眼用医药组合物

Also Published As

Publication number Publication date
UY32225A (es) 2010-06-30
US20100113503A1 (en) 2010-05-06
US8034826B2 (en) 2011-10-11
TW201022265A (en) 2010-06-16
GB2465062A (en) 2010-05-12
WO2010054113A2 (en) 2010-05-14
GB0919199D0 (en) 2009-12-16
WO2010054114A2 (en) 2010-05-14
US20110301168A1 (en) 2011-12-08
GB2465062B (en) 2011-04-13
WO2010054113A3 (en) 2010-08-19
WO2010054114A3 (en) 2010-08-19

Similar Documents

Publication Publication Date Title
AR074089A1 (es) Antagonistas de cicloalcano (b) azaindol de los receptores de la postaglandina d2
AR078495A1 (es) Compuestos policiclicos como antagonistas del receptor de acido lisofosfatidico
AR073319A1 (es) Antagonistas de heteroarilo de receptores de prostaglandina d2
AR074676A1 (es) Derivados de isooxazol como antagonistas de receptores de acido lisofosfatidico, composicion farmaceutica que los comprende y su uso en el tratamiento de enfermedades mediadas por la actividad fisiologica de lpa.
AR077977A1 (es) Compuestos y composiciones como inhibidores de cinasa de proteina
BRPI0714315B8 (pt) arilamidas substituídas com tetrazol, seu uso e composição farmacêutica que as compreende
BR112012033075A2 (pt) composto piperidina substituído antagonista de receptor c5a, composição farmacêutica, e, uso do composto.
AR100442A1 (es) Derivados de pirido[1,2-a]pirimidin-4-ona para tratar atrofia muscular espinal
ECSP10010439A (es) Antagonistas n,n-disustituidos de aminoalquilbifenilo de receptores d2 de prostaglandina
AR078408A1 (es) Derivados de indol como moduladores de los crac
AR086522A1 (es) Inhibidores heterociclicos de autotaxina y usos de los mismos
AR088000A1 (es) Derivados de pirazolquinolinona, su preparacion y su uso terapeutico
ATE552246T1 (de) Substituierte aryloxy-n- bicyclomethylacetamidverbindungen als vr1- antagonisten
EA201001683A1 (ru) Производные фенил- или пиридинилзамещенных индазолов
PE20141598A1 (es) Derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina
CO6400144A2 (es) Derivados aminoéster de alcaloides y composición medicinal de los mismos
AR078536A1 (es) Derivados de pirazol como ligandos del receptor de estrogeno
PE20141380A1 (es) Imidazopiridazinas como inhibidores de quinasa akt
AR065804A1 (es) Compuesto de indol carboxamida, composicion farmaceutica que lo comprende y uso de dicho compuesto para preparar un medicamento
AR077819A1 (es) Compuestos heterociclicos antagonistas de esfingosina -1-fosfato (sip)
AR077969A1 (es) Derivados de (tio)morfolina comomoduladores de s1p
AR074353A1 (es) Acidos naftalen-2-il-aceticos sustituidos, composiciones farmaceuticas que los contienen, y uso de los mismos en el tratamiento de enfermedades alergicas,tales como rinitis, asma y dermatititis atopica.
BRPI1016232A2 (pt) Composto de carbinol, medicamento, regulador de lxr, composição farmacêutica, método para prevenir e/ou tratar doenças, e, uso do composto de carbinol
AR085750A1 (es) Derivados de pirazolo-pirimidina
NI201000195A (es) Derivados de quinuclidina como antagonistas de receptores muscarinicos m3.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal